Bank of America
ALXN

Bank of America’s Alexion Pharmaceuticals ALXN Stock Holding History

Bank of America’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,000
Closed -$1.8M – 7295
2020
Q1 		$1.8M Hold
20,000
– – ﹤0.01% 3563
2019
Q4 		$2.16M Buy
20,000
+14,900
+292% +$1.59M ﹤0.01% 3964
2019
Q3 		$499K Buy
+5,100
New +$575K ﹤0.01% 5090
2019
Q1 		– Sell
-1,200
Closed -$117K – 7551
2018
Q4 		$117K Sell
1,200
-7,300
-86% -$863K ﹤0.01% 5825
2018
Q3 		$1.18M Sell
8,500
-73,700
-90% -$9.25M ﹤0.01% 4373
2018
Q2 		$10.2M Sell
82,200
-34,400
-30% -$4.02M ﹤0.01% 2437
2018
Q1 		$13M Buy
116,600
+83,600
+253% +$9.99M ﹤0.01% 2157
2017
Q4 		$3.95M Buy
33,000
+1,800
+6% +$219K ﹤0.01% 3337
2017
Q3 		$4.38M Buy
31,200
+6,200
+25% +$842K ﹤0.01% 3302
2017
Q2 		$3.04M Buy
+25,000
New +$2.91M ﹤0.01% 3509
2017
Q1 		– Sell
-173,900
Closed -$21.3M – 7358
2016
Q4 		$21.3M Buy
+173,900
New +$21.3M ﹤0.01% 1636
2016
Q3 		– Sell
-24,700
Closed -$2.88M – 7469
2016
Q2 		$2.88M Sell
24,700
-53,000
-68% -$7.52M ﹤0.01% 3302
2016
Q1 		$10.8M Buy
+77,700
New +$11.4M ﹤0.01% 2077
2015
Q4 		– Sell
-17,500
Closed -$2.74M – 7550
2015
Q3 		$2.74M Sell
17,500
-37,800
-68% -$6.9M ﹤0.01% 3467
2015
Q2 		$10M Buy
55,300
+40,300
+269% +$6.95M ﹤0.01% 1931
2015
Q1 		$2.6M Sell
15,000
-20,700
-58% -$3.75M ﹤0.01% 3001
2014
Q4 		$6.61M Sell
35,700
-700
-2% -$130K ﹤0.01% 2303
2014
Q3 		$6.04M Sell
36,400
-48,800
-57% -$8.01M ﹤0.01% 2393
2014
Q2 		$13.3M Buy
85,200
+61,300
+256% +$9.68M ﹤0.01% 1693
2014
Q1 		$3.64M Sell
23,900
-75,600
-76% -$12M ﹤0.01% 2683
2013
Q4 		$13.2M Buy
99,500
+9,000
+10% +$1.08M ﹤0.01% 1605
2013
Q3 		$10.5M Sell
90,500
-13,500
-13% -$1.48M ﹤0.01% 1738
2013
Q2 		$9.59M Buy
+104,000
New +$10M ﹤0.01% 1754

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bank of America's ALXN Position: Q3 2021 in Review

Bank of America sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,429,070 shares — an estimated $263M sold.

Bank of America first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $507M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bank of America reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bank of America sold 1,429,070 Alexion Pharmaceuticals shares in Q3 2021, an estimated $263M.
  • Bank of America first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Bank of America's Alexion Pharmaceuticals position peaked at $507M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bank of America's 13F filing for Q3 2021, filed 15 Nov 2021.